CY1116458T1 - Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων - Google Patents
Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτωνInfo
- Publication number
- CY1116458T1 CY1116458T1 CY20151100576T CY151100576T CY1116458T1 CY 1116458 T1 CY1116458 T1 CY 1116458T1 CY 20151100576 T CY20151100576 T CY 20151100576T CY 151100576 T CY151100576 T CY 151100576T CY 1116458 T1 CY1116458 T1 CY 1116458T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- provides
- malignancies
- role
- antigen
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010066476 Haematological malignancy Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54191104P | 2004-02-06 | 2004-02-06 | |
| US54758404P | 2004-02-26 | 2004-02-26 | |
| US55394804P | 2004-03-18 | 2004-03-18 | |
| US59901404P | 2004-08-06 | 2004-08-06 | |
| US61447104P | 2004-10-01 | 2004-10-01 | |
| EP11196172.8A EP2511297B1 (en) | 2004-02-06 | 2005-02-07 | Anti-CD38 human antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116458T1 true CY1116458T1 (el) | 2017-03-15 |
Family
ID=37054659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100576T CY1116458T1 (el) | 2004-02-06 | 2015-07-02 | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP2915820A1 (enExample) |
| JP (4) | JP2008504013A (enExample) |
| KR (2) | KR20140066259A (enExample) |
| BR (1) | BRPI0507489A (enExample) |
| CY (1) | CY1116458T1 (enExample) |
| DK (2) | DK1720907T3 (enExample) |
| ES (2) | ES2541436T3 (enExample) |
| HR (1) | HRP20150641T1 (enExample) |
| HU (1) | HUE025369T2 (enExample) |
| IL (1) | IL177242A (enExample) |
| ME (1) | ME02245B (enExample) |
| NO (1) | NO20063986L (enExample) |
| NZ (1) | NZ548990A (enExample) |
| PL (1) | PL2511297T3 (enExample) |
| PT (1) | PT2511297E (enExample) |
| RS (1) | RS54056B1 (enExample) |
| SG (1) | SG142330A1 (enExample) |
| WO (1) | WO2005103083A2 (enExample) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| AU2006330411B2 (en) | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| WO2007142241A1 (ja) * | 2006-06-05 | 2007-12-13 | Hiroshima University | 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞 |
| HRP20191115T1 (hr) | 2006-09-26 | 2019-09-20 | Genmab A/S | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora |
| AU2013209322A1 (en) * | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| EP2191841A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| WO2010079189A1 (en) | 2009-01-09 | 2010-07-15 | Morphosys Ag | Display vectors and methods and uses thereof |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| KR20130066682A (ko) * | 2010-10-05 | 2013-06-20 | 다이이찌 산쿄 가부시키가이샤 | 항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５ |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| HUE036518T2 (hu) | 2012-09-25 | 2018-07-30 | Morphosys Ag | Kombinációk és alkalmazásaik |
| DK2914302T3 (en) | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| JP2014117191A (ja) * | 2012-12-13 | 2014-06-30 | Fisheries Research Agency | リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途 |
| HRP20191865T1 (hr) | 2013-01-14 | 2020-01-10 | Xencor, Inc. | Novi heterodimerni proteini |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| ES2774976T3 (es) * | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| BR112016009919A2 (pt) | 2013-11-04 | 2017-12-05 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3954713A3 (en) * | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10106620B2 (en) | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| US10532106B2 (en) | 2014-10-29 | 2020-01-14 | Bicyclerd Limited | Bicyclic peptide ligands specific for MT1-MMP |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| WO2016164656A1 (en) * | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| HRP20210552T1 (hr) | 2015-05-13 | 2021-05-14 | Morphosys Ag | Liječenje multiplog mijeloma (mm) |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| MX2017015493A (es) | 2015-05-30 | 2018-02-09 | Molecular Templates Inc | Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden. |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| HUE066300T2 (hu) | 2015-06-24 | 2024-07-28 | Janssen Biotech Inc | Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| AU2017226960B2 (en) | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| EP3487506A1 (en) | 2016-07-20 | 2019-05-29 | Hybrigenics SA | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
| JP7679196B2 (ja) * | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| CN110997722B (zh) | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| JP7359700B2 (ja) | 2017-06-20 | 2023-10-11 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８抗体薬物コンジュゲート |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| CA3072296A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| CN111032693B (zh) | 2017-08-16 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| JP7036909B2 (ja) * | 2017-10-10 | 2022-03-15 | サノフイ | 抗ｃｄ３８抗体および使用方法 |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201810320D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
| JP2022512722A (ja) | 2018-10-17 | 2022-02-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下投与を提供する方法 |
| BR112021009287A2 (pt) | 2018-11-20 | 2021-10-26 | Janssen Biotech, Inc. | Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| EP3893841A1 (en) | 2018-12-14 | 2021-10-20 | MorphoSys AG | Antibody formulations |
| WO2020128526A1 (en) | 2018-12-21 | 2020-06-25 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| GB201900530D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for CD38 |
| WO2020187718A1 (en) | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| AU2020307667A1 (en) | 2019-06-27 | 2022-01-20 | Crispr Therapeutics Ag | Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer |
| US20220257796A1 (en) | 2019-07-02 | 2022-08-18 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| EP4130035A4 (en) * | 2020-03-31 | 2024-06-26 | Bio-Thera Solutions, Ltd. | Antibody and fusion protein for treating coronaviruses and use thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| EP4596046A3 (en) | 2020-05-21 | 2025-10-22 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP4171585A1 (en) | 2020-06-26 | 2023-05-03 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN114075283A (zh) * | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
| GB202016331D0 (en) | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| US20220202859A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| JP2024503432A (ja) | 2021-01-14 | 2024-01-25 | モルフォシス・アーゲー | 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用 |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| US20220387488A1 (en) | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| US20220378829A1 (en) | 2021-05-12 | 2022-12-01 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating solid tumors |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| MX2024005406A (es) | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38. |
| WO2023098813A1 (en) * | 2021-12-03 | 2023-06-08 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding cd38 and uses thereof |
| EP4472740A1 (en) | 2022-01-31 | 2024-12-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| JP2000316578A (ja) * | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| US7091323B2 (en) * | 2001-04-24 | 2006-08-15 | Bayer Corporation | Human TIMP-1 antibodies |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| JP2008504013A (ja) * | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| AR053489A1 (es) * | 2005-05-24 | 2007-05-09 | Morphosys Ag | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano |
| PT2500360E (pt) | 2005-10-31 | 2015-10-15 | Oncomed Pharm Inc | Composições e métodos para diagnóstico e tratamento do cancro |
| JP2012022417A (ja) * | 2010-07-12 | 2012-02-02 | Humony Co Ltd | 電子請求処理サービスシステム及び該電子請求処理サービスシステム用のアプリケーション |
| JP6257929B2 (ja) * | 2013-06-13 | 2018-01-10 | 東芝メディカルシステムズ株式会社 | Ｘ線コンピュータ断層撮影装置 |
-
2005
- 2005-02-07 JP JP2006551957A patent/JP2008504013A/ja not_active Withdrawn
- 2005-02-07 DK DK05769690.8T patent/DK1720907T3/en active
- 2005-02-07 NZ NZ548990A patent/NZ548990A/en not_active IP Right Cessation
- 2005-02-07 HU HUE11196172A patent/HUE025369T2/en unknown
- 2005-02-07 ES ES05769690.8T patent/ES2541436T3/es not_active Expired - Lifetime
- 2005-02-07 EP EP15151492.4A patent/EP2915820A1/en not_active Ceased
- 2005-02-07 KR KR1020147011314A patent/KR20140066259A/ko not_active Withdrawn
- 2005-02-07 BR BRPI0507489-4A patent/BRPI0507489A/pt not_active Application Discontinuation
- 2005-02-07 KR KR1020137028482A patent/KR20130126747A/ko not_active Abandoned
- 2005-02-07 RS RS20150390A patent/RS54056B1/sr unknown
- 2005-02-07 SG SG200803286-4A patent/SG142330A1/en unknown
- 2005-02-07 EP EP05769690.8A patent/EP1720907B1/en not_active Expired - Lifetime
- 2005-02-07 DK DK11196172.8T patent/DK2511297T3/en active
- 2005-02-07 ES ES11196172.8T patent/ES2541489T3/es not_active Expired - Lifetime
- 2005-02-07 EP EP11196172.8A patent/EP2511297B1/en not_active Revoked
- 2005-02-07 PL PL11196172T patent/PL2511297T3/pl unknown
- 2005-02-07 PT PT111961728T patent/PT2511297E/pt unknown
- 2005-02-07 WO PCT/IB2005/002476 patent/WO2005103083A2/en not_active Ceased
-
2006
- 2006-08-02 IL IL177242A patent/IL177242A/en active IP Right Grant
- 2006-09-05 NO NO20063986A patent/NO20063986L/no not_active Application Discontinuation
-
2012
- 2012-02-03 JP JP2012022417A patent/JP5926568B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-05 JP JP2015000102A patent/JP2015110597A/ja active Pending
- 2015-06-15 HR HRP20150641TT patent/HRP20150641T1/hr unknown
- 2015-07-02 CY CY20151100576T patent/CY1116458T1/el unknown
-
2016
- 2016-05-17 ME MEP-2015-350A patent/ME02245B/me unknown
- 2016-06-03 JP JP2016111794A patent/JP2016164198A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130126747A (ko) | 2013-11-20 |
| KR20140066259A (ko) | 2014-05-30 |
| EP2511297A1 (en) | 2012-10-17 |
| PT2511297E (pt) | 2015-08-24 |
| IL177242A0 (en) | 2006-12-10 |
| JP2016164198A (ja) | 2016-09-08 |
| SG142330A1 (en) | 2008-05-28 |
| DK2511297T3 (en) | 2015-06-15 |
| HK1097859A1 (en) | 2007-07-06 |
| JP5926568B2 (ja) | 2016-05-25 |
| NZ548990A (en) | 2009-06-26 |
| IL177242A (en) | 2011-09-27 |
| JP2012116856A (ja) | 2012-06-21 |
| ES2541489T3 (es) | 2015-07-21 |
| EP1720907A2 (en) | 2006-11-15 |
| ME02245B (me) | 2015-10-30 |
| EP2915820A1 (en) | 2015-09-09 |
| HUE025369T2 (en) | 2016-02-29 |
| ES2541436T3 (es) | 2015-07-20 |
| WO2005103083A2 (en) | 2005-11-03 |
| RS54056B1 (sr) | 2015-10-30 |
| EP2511297B1 (en) | 2015-04-08 |
| NO20063986L (no) | 2006-11-06 |
| WO2005103083A8 (en) | 2006-10-05 |
| HRP20150641T1 (hr) | 2015-07-17 |
| DK1720907T3 (en) | 2015-06-15 |
| PL2511297T3 (pl) | 2015-08-31 |
| BRPI0507489A (pt) | 2007-07-10 |
| JP2015110597A (ja) | 2015-06-18 |
| EP1720907B1 (en) | 2015-04-08 |
| WO2005103083A3 (en) | 2006-11-16 |
| JP2008504013A (ja) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116458T1 (el) | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| CY1125427T1 (el) | Anti-gm-csf αντισωματα και χρησεις αυτων | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| CY1122627T1 (el) | Αντισωματα εναντι της ceacam6 και χρησεις αυτων | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| JOP20190116A1 (ar) | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها | |
| CY1117437T1 (el) | Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| CY1119051T1 (el) | Αντισωματα anti-c4.4a και χρησεις αυτων | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| CR20190594A (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| BR112022001368A2 (pt) | Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos | |
| NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
| CY1115634T1 (el) | Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| CY1124762T1 (el) | Αναστολεις πρωτεïνης δεσμευσης creb (cbp) | |
| PH12021551422A1 (en) | Anti-il-36 antibodies and methods of use thereof | |
| ZA202110285B (en) | Antibodies and methods of use | |
| MX2011008456A (es) | Anticuerpos anti-mst1r y usos de los mismos. | |
| ATE470478T1 (de) | An ovarialkrebs beteiligtes protein |